Natural Capsules Limited has reported a 2.18% dilution in its equity stake in subsidiary Natural Biogenex Private Limited following its decision not to subscribe to the subsidiary's recent rights issue. This strategic move, approved by the Board of Directors on July 28, 2026, reduces the parent company's holding from 68.96% to 66.78%, though Natural Biogenex remains a controlled subsidiary. The decision reflects a deliberate allocation of capital toward other business priorities rather than maintaining pro-rata ownership in the loss-making entity.

The Board passed a resolution by circulation, with the final majority vote received by 08:00 PM on July 28, 2026, formally opting out of the subscription period which ran from July 14, 2026, to July 28, 2026. Consequently, shares were allotted to other investors and applicants, resulting in the dilution. The company disclosed this development pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notifying both the Bombay Stock Exchange and the National Stock Exchange.

Subsidiary Financial Position

The dilution occurs against a backdrop of significant financial stress at Natural Biogenex Private Limited. For the last financial year, the subsidiary reported a turnover of ₹13.43 crore but incurred a substantial loss of ₹43.30 crore. Despite these operational losses, the subsidiary maintains a net worth of ₹81.24 crore. The parent company's decision to avoid further capital infusion into a loss-making unit suggests a focus on preserving cash for core operations or higher-return opportunities elsewhere.

Shareholding Structure Changes

Prior to the rights issue, Natural Capsules Limited held 1,99,99,996 equity shares, representing 68.96% of the paid-up capital of Natural Biogenex. Post-allotment, the absolute number of shares held by the parent company remains unchanged at 1,99,99,996. However, due to the issuance of new shares to third-party applicants, the percentage holding has decreased to 66.78% of the revised paid-up capital. Crucially, the entity continues to be classified as a subsidiary, meaning Natural Capsules retains control over its operations and financial policies.

Strategic Rationale

The company cited "strategic allocation of funds on other business matters" as the primary reason for non-participation. This indicates that management has prioritized capital deployment in areas potentially offering better returns or addressing more urgent liquidity needs than supporting Natural Biogenex's capital requirements. The transaction is not classified as a related party transaction, as the dilution resulted from allotment to third parties rather than a transfer between related entities. Akshay Dutta, Company Secretary and Compliance Officer, signed the disclosure dated July 29, 2026, from Bangalore.

Natural Capsules Limited has completed the electronic dispatch of its Annual Report for the financial year 2025-26 on July 17, 2026. The company informed the exchanges that the Notice of the 33rd Annual General Meeting (AGM) and the Integrated Annual Report are available on its website and the websites of the stock exchanges. The AGM is scheduled to be held on Wednesday, August 12, 2026, at 12:00 PM IST via Video Conferencing (VC) or Other Audio Visual Means (OAVM) at the registered office in Bengaluru, Karnataka.

The agenda includes the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026. Shareholders will vote on the re-appointment of directors Mrs. Jyoti Mundra and Mr. Laxminarayan Moondra, who retire by rotation. Additionally, the company seeks approval for the re-appointment of Mr. Laxminarayana Moondra as Whole Time Director for a term of 3 years effective August 20, 2026, with a revised remuneration package.

Special business includes approving related party transactions with subsidiary Natural Biogenex Private Limited. The company seeks approval to enter into contracts and provide unsecured loans up to ₹ 50 crores until the conclusion of the next AGM. The funds, sourced from internal accruals, will be utilized for future capital expenditure and meeting working capital requirements. Interest will be charged at the bank rate applicable to the company.

Shareholders will also consider revising the remuneration of Mr. Shrey Mundra, General Manager – Marketing, a related party. His gross remuneration is proposed to increase from ₹ 2,25,000 to ₹ 2,50,000 per month from April 1, 2026, and to ₹ 2,75,000 per month thereafter for one year. The Board has recommended these resolutions, with the re-appointment of the Whole Time Director requiring a special resolution and other items requiring ordinary resolutions.

Remote e-voting will commence on August 8, 2026, at 09:00 AM and conclude on August 11, 2026, at 05:00 PM. Members can cast votes electronically through the NSDL e-voting system. The facility for attending the AGM via VC/OAVM is available on a first-come-first-served basis for 1,000 members, excluding large shareholders holding more than 2% of shares and institutional investors.

Key AGM Dates